Joshua J. Meeks, MD, PhD, discussed the emerging role of ctDNA in guiding adjuvant and neoadjuvant strategies in patients with bladder cancer.
News Network: Bladder Cancer at SUO 2025
Michael S. Cookson, MD, MMHC, FACS, shares his thoughts on the most exciting recent advances in bladder cancer treatment.
Laura Bukavina, MD, MPH, offered her thoughts on the significance of the KEYNOTE-905 data and highlighted some remaining questions surrounding the regimen.
Siamak Daneshmand, MD, emphasizes that, at present, optimal patient selection remains unclear because resistance mechanisms and predictive biomarkers are not yet well understood.
Eugene Pietzak, MD, highlights the background and design of the ongoing phase 3 GAIN trial, exploring the combination of gemcitabine and BCG in BCG-exposed NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Beyond the clinic: Physician presence on social media
2
FDA updates in urology: December 2025
3
Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions
4
Study validates Decipher as a predictor of early biochemical recurrence in prostate cancer
5